论文部分内容阅读
日本药学研究生产机构在昭和50年代至平成4年间(1975年—1992年)新药开发种类大致有以下几个方面:组织胺H_2拮抗剂、降压剂分支血管紧张素转换酶阻断剂、抗癌剂、免疫制剂、铂配位化合物及喹诺酮类合成抗菌剂等疗效可靠的药物纷纷上市。消化性溃疡治疗药,如攻击因子药和防御因子药物的研究都有了长足有进步。特别是H_2—受体拮抗剂的出现,攻击因子药的治疗观念,以抑制胃液分泌机制主体的组织胺受体,对胃酸分泌有强力抑制作用的药物西咪替丁,于1982年藤泽制药公司推向市场(Cimetidine,商品名Tagmet);三共制药公司的雷尼替丁(ranitidine,1983年);田边制药于81年推出毒蕈碱受体选择性抑制剂,如抑制胃酸分
Japanese pharmaceutical research and manufacturing institutions in the Showa 50s to Heisei 4 years (1975-1992 years) the types of new drug development generally have the following aspects: histamine H 2 antagonist, antihypertensive agents branching angiotensin converting enzyme blockers, anti Curatives such as cancer agents, immunosuppressants, platinum coordination compounds and quinolone antibacterial agents are listed on the market. Peptic ulcer treatment drugs, such as the attack factor drugs and defense factor drugs have made considerable progress. In particular, the emergence of H 2 -receptor antagonists, the therapeutic concept of aggressive factor drugs, the histamine receptor that suppresses the body’s main mechanism of gastric fluid secretion, the drug cimetidine that strongly suppresses gastric acid secretion, and the Fujitsu Pharmaceutical (Cimetidine, trade name Tagmet); ranitidine (1983) by Sankyo; Tanabe Pharma introduced selective inhibitors of muscarinic receptors in 81 such as inhibition of gastric acid